| 30.94 1.12 (3.76%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 38.29 | 1-year : | 44.73 |
| Resists | First : | 32.79 | Second : | 38.29 |
| Pivot price | 24.15 |
|||
| Supports | First : | 24.47 | Second : | 19.34 |
| MAs | MA(5) : | 30.38 |
MA(20) : | 23.32 |
| MA(100) : | 19.12 |
MA(250) : | 12.31 |
|
| MACD | MACD : | 1.9 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 77.7  |
D(3) : | 79.8 |
| RSI | RSI(14): 65.5 |
|||
| 52-week | High : | 32.79 | Low : | 4.4 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TNGX ] has closed below upper band by 12.6%. Bollinger Bands are 189.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 31.74 - 31.86 | 31.86 - 31.95 |
| Low: | 29.17 - 29.31 | 29.31 - 29.43 |
| Close: | 30.72 - 30.95 | 30.95 - 31.13 |
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Fri, 12 Jun 2026
symbol__ Stock Quote Price and Forecast - CNN
Fri, 12 Jun 2026
Tango Therapeutics prices upsized $600M public offering at $30/share - MSN
Wed, 10 Jun 2026
Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option Granted - TradingView
Wed, 10 Jun 2026
Tango Therapeutics (NASDAQ: TNGX) prices $566.5M stock and warrant offering - Stock Titan
Tue, 09 Jun 2026
Tango Therapeutics prices $600 million stock offering - Investing.com
Tue, 09 Jun 2026
Tango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 163 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 113.8 (%) |
| Shares Short | 33,490 (K) |
| Shares Short P.Month | 38,250 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.54 |
| Profit Margin | -188.2 % |
| Operating Margin | -206.3 % |
| Return on Assets (ttm) | -20.7 % |
| Return on Equity (ttm) | -38.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.45 |
| Sales Per Share | 0.35 |
| EBITDA (p.s.) | -0.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -142 (M) |
| Levered Free Cash Flow | -68 (M) |
| PE Ratio | -37.28 |
| PEG Ratio | 0 |
| Price to Book value | 12.13 |
| Price to Sales | 88.38 |
| Price to Cash Flow | -35.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|